{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-018314","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.902263+00:00","generated_at":"2026-05-16T01:20:08.608801+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Gilead to acquire Arcellx for $115/share plus $5 CVR; implied equity value $7.8B","bullets":["$115 per share cash at closing plus one contingent value right of $5 per share; total implied equity value ~$7.8B.","CVR pays $5 if cumulative worldwide sales of anito-cel exceed $6B by Dec 31, 2029.","FDA accepted BLA for anito-cel in relapsed/refractory multiple myeloma; PDUFA date Dec 23, 2026.","Transaction expected to close Q2 2026; requires majority tender, regulatory approvals, and customary conditions.","Gilead currently owns ~11.5% of Arcellx; deal builds on existing Kite collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-018314","json":"https://secwatch.observer/filing/0001104659-26-018314.json","markdown":"https://secwatch.observer/filing/0001104659-26-018314.md","text":"https://secwatch.observer/filing/0001104659-26-018314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000110465926018314/0001104659-26-018314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000110465926018314/tm267044d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:20:08.608801+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"126ba01f7470f6918022bb1b786eb52163455c2d","claim":"GILEAD SCIENCES, INC. entered into Merger Agreement with Arcellx, Inc. (effective 2026-02-22).","evidence_excerpt":"On February 22, 2026, Gilead Sciences, Inc., a Delaware corporation (“ Parent ” or “ Gilead ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), among Parent, Arcellx, Inc., a Delaware corporation (the “ Company ”), and Ravens Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882095/000110465926018314/0001104659-26-018314-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Arcellx, Inc."},{"label":"Effective","value":"2026-02-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}